ADAR1 Capital Management LLC Lowers Stock Holdings in PolyPid Ltd. (NASDAQ:PYPD)

ADAR1 Capital Management LLC reduced its position in PolyPid Ltd. (NASDAQ:PYPD) by 14.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 80,080 shares of the company’s stock after selling 13,822 shares during the quarter. ADAR1 Capital Management LLC’s holdings in PolyPid were worth $243,000 at the end of the most recent quarter.

Separately, AIGH Capital Management LLC boosted its stake in shares of PolyPid by 21.8% in the fourth quarter. AIGH Capital Management LLC now owns 827,867 shares of the company’s stock valued at $2,509,000 after purchasing an additional 148,199 shares during the period. 26.47% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

PYPD has been the topic of several recent research reports. HC Wainwright cut their target price on shares of PolyPid from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, December 26th. RODMAN&RENSHAW raised PolyPid to a “strong-buy” rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw began coverage on PolyPid in a research note on Tuesday, January 28th. They issued a “buy” rating and a $13.00 price objective on the stock.

PolyPid Stock Down 4.0 %

PYPD stock opened at $2.41 on Tuesday. The company’s 50 day moving average price is $2.89 and its 200 day moving average price is $3.14. The firm has a market capitalization of $24.56 million, a price-to-earnings ratio of -0.48 and a beta of 1.28. PolyPid Ltd. has a fifty-two week low of $2.30 and a fifty-two week high of $5.09. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.00 and a current ratio of 1.31.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($1.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.23). On average, equities research analysts anticipate that PolyPid Ltd. will post -1.79 EPS for the current fiscal year.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.